Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy
BackgroundImmune-mediated necrotizing myopathy (IMNM) is a rare autoimmune disease. Efgartigimod is a human IgG antibody Fc fragment, can enhance the degradation of IgG and thus may be a promising therapeutic agent for IMNM.MethodsAll three patients exhibited proximal muscle weakness and markedly in...
Saved in:
| Main Authors: | Qiqi Peng, Xiaoping Yao, Sheng Chen, Xiaofeng Li, Feifei Lin, Zhangyu Zou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1560483/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis
by: Jia-Jun Cheng, et al.
Published: (2025-08-01) -
Case report: Rapid clinical improvement of anti-HMGCR immune-mediated necrotizing myopathy treated with efgartigimod
by: Quantao Zeng, et al.
Published: (2024-11-01) -
Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases
by: Tianying Ma, et al.
Published: (2025-01-01) -
Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report
by: Huasheng Huang, et al.
Published: (2025-01-01) -
Pediatric immune-mediated necrotizing myopathy with anti-SRP antibodies targeting 19, 68, and 72 kda subunits
by: Daigo Kato, et al.
Published: (2025-06-01)